ADAR1 Capital Management’s Dianthus Therapeutics DNTH Stock Holding History

ADAR1 Capital Management’s Portfolio DNTH Stock Details DNTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-55,000	Closed	-$4.62M	–	298
2026 Q1	$4.62M	Buy	+55,000	New	+$3.19M	0.27%	82
2025 Q2	–	Sell	-18,285	Closed	-$332K	–	218
2025 Q1	$332K	Buy	18,285 +602	+3%	+$13.3K	0.06%	123
2024 Q4	$385K	Sell	17,683 -101,055	-85%	-$2.6M	0.08%	122
2024 Q3	$3.25M	Buy	+118,738	New	+$3.31M	0.53%	37
2024 Q1	–	Sell	-481	Closed	-$5K	–	274
2023 Q4	$5K	Buy	+481	New	+$5.31K	﹤0.01%	144

Other funds holding DNTH

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

ADAR1 Capital Management's DNTH Position: Q2 2026 in Review

ADAR1 Capital Management sold out of Dianthus Therapeutics (DNTH) in Q2 2026, closing a stake of 55,000 shares — an estimated $4.62M sold.

ADAR1 Capital Management first reported a position in DNTH in Q4 2023 and held it in 5 quarters. The position peaked at $4.62M in Q1 2026. 270 funds tracked by Wall St. Rank hold DNTH as of Q2 2026.

ADAR1 Capital Management reported no remaining Dianthus Therapeutics position as of Q2 2026 after selling out during the quarter.
ADAR1 Capital Management sold 55,000 Dianthus Therapeutics shares in Q2 2026, an estimated $4.62M.
ADAR1 Capital Management first reported a position in Dianthus Therapeutics in Q4 2023 and held it in 5 quarters.
ADAR1 Capital Management's Dianthus Therapeutics position peaked at $4.62M in Q1 2026.
270 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2026.

Based on ADAR1 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.